Entasis Therapeutics Hldgs Inc

Entasis Therapeutics Holdings Inc. (https://www.entasistx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant pathogens. Its lead product candidate is Sulbactam-durlobactam (SUL-DUR), which is an IV antibiotic with broad spectrum b-lactamase coverage. The Company’s pipeline includes sulbactam-durlobactam (ETX2514SUL), zoliflodacin, ETX0282CPDP and ETX0462. ETX2514SUL is a fixed-dose combination with b-lactams. Zoliflodacin as a single dose, oral antibiotic monotherapy. ETX0282CPDP is an oral fixed-dose combination of ETX0282 with cefpodoxime proxetil. The pipeline includes programs for differentiated medicines to treat multidrug-resistant Gram-negative infections, such as Pseudomonas aeruginosa, Acinetobacter baumanii, carbapenem-resistant Enterobacteriaceae and Neisseria gonorrhoeae.

• Entasis Therapeutics Hldgs Inc